🇺🇸 FDA

Intelligence · Clinical Pipeline

Sinovac Research and Pipeline

All ClinicalTrials.gov programs at Sinovac Research and — phase, modality, and trial IDs.

Programs
115

Quick answer

Sinovac Research and has 115 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Single-dose regimen of high dosage investigational sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    phase 2 mab completed

    1 trial

  2. Sinovac Low-dosage PCV24

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 2 mab completed

    1 trial

  3. Sinovac PCV24

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 2 mab active

    2 trials

  4. Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial

  5. Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    2 trials

  6. low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    phase 2 mab active

    1 trial

  7. pandemic influenza vaccine (H5N1 strain NIBRG-14)

    Sinovac Research and Development Co.,

    Pandemic Influenza

    phase 2 mab completed

    1 trial

  8. 100U inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Hand-foot-mouth Disease

    phase 1 mab completed

    1 trial

  9. Inactivated Enterovirus Type 71 Vaccine

    Sinovac Research and Development Co.,

    Infection; Viral, Enterovirus

    phase 1 mab completed

    1 trial

  10. Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    phase 1 mab completed

    1 trial

  11. Low-dose RSV mRNA vaccine

    Sinovac Research and Development Co.,

    RSV

    phase 1 mab active

    1 trial

  12. One dose of investigational vaccine

    Sinovac Research and Development Co.,

    Hepatitis B

    phase 1 mab completed

    1 trial

  13. SA55 Injection

    Sinovac Research and Development Co.,

    COVID-19

    phase 1 small molecule active

    1 trial

  14. SA55 nasal spray

    Sinovac Research and Development Co.,

    COVID-19

    phase 1 small molecule active

    1 trial

  15. Sinovac PCV24 formulation 1

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 1 mab completed

    2 trials

  16. an inactivated whole virion H5N1 vaccine, adjuvanted

    Sinovac Research and Development Co.,

    Influenza

    phase 1 mab completed

    1 trial

  17. high-dose Group ACYW135X Meningococcal Conjugate Vaccine

    Sinovac Research and Development Co.,

    Meningococcal Meningitis

    phase 1 mab active

    1 trial

  18. pandemic influenza vaccine (H5N1 strain NIBRG-14)

    Sinovac Research and Development Co.,

    Pandemic Influenza Vaccine

    phase 1 mab completed

    1 trial

  19. 2 doses of HAV

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial

  20. 2012-2013 trivalent seasonal influenza vaccine

    Sinovac Research and Development Co.,

    Influenza

    approved mab completed

    1 trial

  21. 2wIPV+1sIPV

    Sinovac Research and Development Co.,

    Poliomyelitis

    approved mab active

    1 trial

  22. 5000 volunteers (6-35 months)-EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial

  23. Adult group in immunogenicity and safety study of combined immunization

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  24. COVID-19 Vaccine (Vero cell), Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  25. Combined vaccination with quadrivalent influenza vaccine and 23-valent pneumococcal polysaccharide vaccine

    Sinovac Research and Development Co.,

    Influenza and Pneumonia

    approved mab completed

    1 trial

  26. Concomitant administration of EV71 vaccine with EPI vaccines

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial

  27. Concomitant administration of EV71vaccine with EPI vaccines

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial

  28. EV71 Vaccine

    Sinovac Research and Development Co.,

    EV71 Vaccine

    approved mab completed

    1 trial

  29. EV71 inactived vaccine（Vero cells）

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial

  30. EV71 vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab completed

    1 trial

  31. Experimental 23-valent PPV

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    1 trial

  32. Experimental 23-valent Pneumococcal

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    1 trial

  33. Experimental Group

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    4 trials

  34. Experimental Vaccine

    Sinovac Research and Development Co.,

    Hand, Foot and Mouth Disease

    approved mab active

    1 trial

  35. Experimental vaccine 1

    Sinovac Research and Development Co.,

    COVID-19

    approved mab on hold

    1 trial

  36. H1N1 influenza A Vaccine (PANFLU.1)

    Sinovac Research and Development Co.,

    Influenza

    approved mab completed

    1 trial

  37. H1N1 influenza A Vaccine (Split virion), Inactivated

    Sinovac Research and Development Co.,

    Influenza

    approved mab completed

    1 trial

  38. Healive (hepatitis A vacine(human diploid cell), inactivated)

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab active

    1 trial

  39. Healive+Healive

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial

  40. Healive® Lot 1

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial

  41. High-dosage SARS-CoV-2 vaccine

    Sinovac Research and Development Co.,

    COVID-19

    approved mab active

    1 trial

  42. High-dosage of COVID-19 vaccine (Vero cell), Inactivated

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  43. Inactivated HAV vaccine

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial

  44. Inactivated Hepatitis A vaccine (HAV)

    Sinovac Research and Development Co.,

    Hepatitis A

    approved mab completed

    1 trial

  45. Inactivated SARS-CoV-2 Vaccine (Vero cell) Lot 1 of the workshop 2

    Sinovac Research and Development Co.,

    COVID-19

    approved mab active

    1 trial

  46. Inactivated SARS-CoV-2 Vaccine (Vero cell）

    Sinovac Research and Development Co.,

    COVID-19

    approved mab completed

    1 trial

  47. Investigational 23-valent PPV

    Sinovac Research and Development Co.,

    Pneumococcal Infections

    approved mab completed

    2 trials

  48. Investigational live attenuated varicella vaccine

    Sinovac Research and Development Co.,

    Varicella

    approved mab active

    4 trials

Frequently asked questions

How many pipeline programs does Sinovac Research and have?

115 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.